Published 2 days ago • loading... • Updated 1 day ago

Gilead, MSD Share Data on Once-Weekly Oral HIV Treatment

Gilead/MSD's once-weekly oral medicine for HIV has been shown to achieve high rates of viral suppression in phase 3, setting up regulatory filings.

6 Articles

Pharmaphorum

Center

Gilead, MSD share data on once-weekly oral HIV treatment

Gilead/MSD's once-weekly oral medicine for HIV has been shown to achieve high rates of viral suppression in phase 3, setting up regulatory filings.

1 day ago

Read Full Article

Dallas Voice

Left

Gilead, Merck announce new results from ISLEN trials

Gilead and Merck today (Tuesday, July 21) announced new results from the Phase 3 ISLEND-1(NCT06630286) andISLEND-2(NCT06630299) trials evaluating the treatment responses of people living with HIV with virological suppression who switched from BIKTARVY® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) or a standard of care oral daily antiretroviral regimen to an investigational once-weekly single-tablet regim…

2 days ago

Read Full Article

Portfolio

An Important Step in the Fight Against the Dreaded Virus: an Anti-HIV Pill Will Soon Be Ready

Gilead Sciences and Merck said their once-weekly experimental HIV drug successfully suppressed the virus in two late-stage clinical trials, in what could be the first such treatment for the disease if approved, Reuters reported.

1 day ago·Budapest, Hungary

Read Full Article

endpoints.news

Gilead and Merck provide HIV data; Dimension Capital announces $800M fund

Gilead and Merck’s HIV data: The duo will present more detailed results of the Phase 3 trials of their once-weekly oral HIV treatment regimen at AIDS 2026, one of the largest ...

2 days ago

Read Full Article